Short communication: the cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004
Cargando...
Fecha
2012
Título de la revista
Publicado en
Tropical medicine and international health, 1365-3156, Vol. 12, Nro. 12, 2012, p. 1540-1544
Publicado por
Wiley-Blackwell
Enlace a contenidos multimedia
ISSN de la revista
Título del volumen
Resumen
Descripción
Abstract
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277–488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226–21 532).
Palabras clave
Keywords
Cost-effectiveness analysis, Leishmaniasis, Prevention and control, Treatment